KeyBanc analyst KeyBanc maintained a Buy rating on Brooks Automation (NASDAQ:BRKS) on Wednesday, setting a price target of $111, which is approximately 30.14% above the present share price of $85.29.
expects Brooks Automation to post earnings per share (EPS) of $0.35 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Brooks Automation, with an average price target of $93.67.
The analysts price targets range from a high of $111 to a low of $70.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $249.5 million and a net profit of $31.02 million. The company's market cap is $6.33 billion.
According to TipRanks.com, KeyBanc analyst KeyBanc is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.1% and a 66.79% success rate.
Brooks Automation, Inc. engages in the provision of automation and cryogenic solutions for multiple markets, including semiconductor capital equipment and life science biological sample management and storage. It operates through the Brooks Semiconductor Solutions Group and Brooks Life Sciences segments. The Brooks Semiconductor Solutions Group segment include atmospheric and vacuum robots, robotic modules and tool automation systems that provide precision handling and clean wafer environments, as well as cryogenic pumps and compressors that provide vacuum pumping and thermal management solutions used to create and control critical process vacuum applications. The Brooks Life Sciences segment provides automated cold sample management systems for compound and biological sample storage, equipment for sample preparation and handling, consumables, and parts and support services to a range of life science customers including pharmaceutical companies, biotechnology companies, bio-banks and research institutes. The company was founded in 1978 and is headquartered in Chelmsford, MA.